Starpharma Holdings Ltd (ASX: SPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Starpharma Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $40.48 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 417.37 million
Earnings per share -0.022
Dividend per share N/A
Year To Date Return -44.12%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Starpharma Holdings Ltd (ASX: SPL)
    Latest News

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    2 ASX healthcare shares outperforming peers on positive company news

    Mesoblast has announced the resolution of a class action law suit against it today.

    Read more »

    Two excited woman pointing out a bargain opportunity on a laptop.
    Cheap Shares

    5 potentially cheap ASX shares being bought by insiders

    Insiders see value in these companies.

    Read more »

    A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
    Healthcare Shares

    3 ASX healthcare shares up 10% to 22% on news

    These healthcare shares are catching the eye on Wednesday. But why?

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Share Gainers

    Why Delta Lithium, Liontown, Pact, and Starpharma shares are storming higher

    These ASX shares are rising despite the market weakness.

    Read more »

    A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
    Healthcare Shares

    Here's why the Starpharma share price just exploded 50%!

    This biotech is catching the eye of investors on Wednesday. But why?

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Earnings Results

    4 ASX healthcare shares charging higher on positive earnings updates

    These ASX healthcare shares are recording strong share price gains today.

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why IGO, Patriot Battery Metals, Silver Lake, and Starpharma shares are sinking today

    These ASX shares are starting the week in the red.

    Read more »

    A man slumps crankily over his morning coffee as it pours with rain outside.
    Healthcare Shares

    Why is this ASX All Ords share sinking 34% on Monday?

    Investors have been selling off this healthcare share due to some bad news.

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking

    These ASX shares are having a tough time on Tuesday.

    Read more »

    a woman holds her hands up in delight as she sits in front of her lap
    Share Gainers

    Why AGL, Retail Food Group, Starpharma, and TPG shares are rising today

    These ASX shares have avoided the market selloff...

    Read more »

    three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
    Share Gainers

    Why Bendigo Bank, Block, Megaport, and Starpharma shares are rising today

    These ASX shares are on form on Tuesday...

    Read more »

    a woman holds a cup to her ear and leans in with a wide mouthed expression on her face as though she is listening to interesting and perhaps surprising information.
    52-Week Lows

    5 ASX shares trading near 52-week lows that insiders have been buying

    Insiders appear to believe these shares are trading at attractive prices.

    Read more »

    Frequently Asked Questions

    No, Starpharma does not pay dividends at this time.

    Starpharma listed on the ASX on 28 September 2000.

    SPL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Starpharma Holdings Ltd

    Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.

    Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.

    Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.

    VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.

    SPL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    03 Oct 2024 $0.10 $0.00 0.00% 389,119 $0.10 $0.10 $0.10
    02 Oct 2024 $0.10 $0.00 0.00% 62,059 $0.10 $0.10 $0.10
    01 Oct 2024 $0.10 $0.00 0.00% 51,504 $0.10 $0.10 $0.10
    30 Sep 2024 $0.10 $0.00 0.00% 745,911 $0.10 $0.11 $0.10
    27 Sep 2024 $0.10 $0.00 0.00% 151,033 $0.10 $0.10 $0.10
    26 Sep 2024 $0.10 $0.00 0.00% 2,026,578 $0.11 $0.11 $0.10
    25 Sep 2024 $0.10 $0.00 0.00% 285,178 $0.10 $0.11 $0.10
    24 Sep 2024 $0.10 $0.00 0.00% 31,012 $0.10 $0.10 $0.10
    23 Sep 2024 $0.10 $0.00 0.00% 148,318 $0.11 $0.11 $0.10
    20 Sep 2024 $0.11 $0.00 0.00% 161,870 $0.11 $0.11 $0.10
    19 Sep 2024 $0.11 $0.01 10.20% 672,668 $0.10 $0.11 $0.10
    18 Sep 2024 $0.10 $0.00 0.00% 232,254 $0.10 $0.11 $0.10
    17 Sep 2024 $0.10 $0.00 0.00% 364,708 $0.10 $0.10 $0.10
    16 Sep 2024 $0.10 $0.00 0.00% 1,987,987 $0.10 $0.11 $0.10
    13 Sep 2024 $0.09 $0.00 0.00% 320,893 $0.09 $0.10 $0.09
    12 Sep 2024 $0.09 $0.00 0.00% 782,124 $0.09 $0.09 $0.09
    11 Sep 2024 $0.09 $0.00 0.00% 763,765 $0.09 $0.09 $0.09
    10 Sep 2024 $0.09 $0.00 0.00% 91,892 $0.10 $0.10 $0.09
    09 Sep 2024 $0.10 $0.00 0.00% 204,301 $0.10 $0.10 $0.10
    06 Sep 2024 $0.10 $0.00 0.00% 212,882 $0.10 $0.10 $0.10
    05 Sep 2024 $0.10 $0.00 0.00% 217,909 $0.10 $0.10 $0.10
    04 Sep 2024 $0.10 $0.00 0.00% 478,500 $0.10 $0.10 $0.10

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    13 Sep 2024 Russell Basser Buy 200,000 $18,600
    On-market trade.
    02 Sep 2024 Robert Thomas Buy 350,000 $3,246
    On-market trade.
    02 Sep 2024 David McIntyre Buy 405,886 $3,879
    On-market trade. As per announcement on 02-09-2024
    28 Jun 2024 Jeff Davies Buy 879,687 $79,699
    On-market trade.
    26 Jun 2024 Robert Thomas Buy 200,000 $17,800
    On-market trade.
    25 Jun 2024 Lynda Cheng Buy 110,555 $9,950
    On-market trade.
    20 Jun 2024 Robert Thomas Buy 250,000 $22,679
    On-market trade.
    30 May 2024 Cheryl Maley Buy 125,000 $14,065
    On-market trade.
    29 May 2024 Robert Thomas Buy 150,000 $17,750
    On-market trade.
    15 Apr 2024 Robert Thomas Buy 100,000 $13,000
    On-market trade.
    12 Apr 2024 Russell Basser Buy 71,428 $10,002
    On-market trade.
    10 Apr 2024 Robert Thomas Buy 250,000 $43,424
    On-market trade.
    08 Dec 2023 Jacinth (Jackie) Fairley Issued 667,441 $90,104
    Issue of securities. 6,432,648 Performance Rights
    06 Oct 2023 Jacinth (Jackie) Fairley Expiry 514,918 $69,513
    As advised by the company. 5,765,207 Performance Rights, lapsed

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Robert Bain Thomas Non-Executive DirectorNon-Executive Chairman Dec 2013
    Mr Thomas has background in financial services and capital markets and is a non-executive director of several Australian listed companies. He was previously a Partner of Potter Partners (now UBS), where he was also Head of Research. He is a member of Risk Committee.
    Ms Cheryl Ann Maley Chief Executive OfficerManaging Director Jan 2024
    Ms Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals.
    Mr David McIntyre Non-Executive Director Mar 2020
    Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. He is the Chair of Risk Committee.
    Ms Lynda Cheng Non-Executive Director Aug 2021
    Ms Cheng has over 25 years of experience as a finance executive, including substantial international experience and several non-executive directorships, Ms Cheng's experience covers the majority of key areas described in Starpharma's Board skills matrix. In particular, she has expertise in accounting/corporate finance, audit and risk; M&A/capital markets; strategy and risk management; governance; as well as business development. Ms Cheng has had involvement in the commercialisation of new innovations during her tenure at South East Water and also while working with disruptive technology companies in Silicon Valley. She is a member of Risk Committee.
    Dr Jeff Davies Non-Executive Director Apr 2022
    Dr Davies has over 35 years of experience within the biopharmaceutical industry, Dr Davies is an accomplished executive skilled in R&D, product development and commercialisation strategy, business development, manufacturing and clinical and regulatory affairs. Dr Davies has leadership skills and experience in commercialising scientific research for healthcare products.
    Dr Russell Basser Non-Executive Director Feb 2023
    Dr Basser has over 20 years of executive experience in the biotechnology industry and 10 years as a practicing clinical oncologist, Dr Basser has leadership skills and experience in healthcare/scientific research; pharmaceutical product development; international executive experience and skills in regulation/public policy; commercialisation of innovation; business development; governance; strategy; and risk management.
    Mr Justin Cahill Chief Financial OfficerCompany Secretary Apr 2023
    -
    Justin Cahill Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 81,247,474 19.70%
    JP Morgan Nominees Australia PTY Limited 31,174,308 7.56%
    Citicorp Nominees Pty Limited 15,203,959 3.69%
    BNP Paribas Noms Pty Ltd 14,494,331 3.51%
    Bell Potter Nominees Ltd <Bb Nominees A/C> 9,000,000 2.18%
    Ingot Capital Investments Pty Ltd 8,705,000 2.11%
    T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> 5,060,000 1.23%
    BNP Paribas Nominees Pty Ltd <Clearstream> 4,866,370 1.18%
    Mr Kingsley Bryan Bartholomew 4,612,025 1.12%
    Lavya Pty Ltd <Lavya Family A/C> 4,344,628 1.05%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 4,267,008 1.03%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,141,107 1.00%
    Mr Peter Murray Jackson 3,921,959 0.95%
    E Equities Pty Ltd 3,700,000 0.90%
    All States Finance Pty Limited 3,500,000 0.85%
    Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> 3,361,550 0.82%
    Ms Jacinth Fairley 3,252,386 0.79%
    Charles & Cornelia Goode Foundation Pty Ltd <CCG Foundation A/C> 3,200,000 0.78%
    Mr Thomas Argyrou 3,000,000 0.73%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> 2,739,822 0.66%

    Profile

    since

    Note